Literature DB >> 23008305

Noninitiation of adjuvant chemotherapy in women with localized breast cancer: the breast cancer quality of care study.

Alfred I Neugut1, Grace Clarke Hillyer, Lawrence H Kushi, Lois Lamerato, Nicole Leoce, S David Nathanson, Christine B Ambrosone, Dana H Bovbjerg, Jeanne S Mandelblatt, Carol Magai, Wei Yann Tsai, Judith S Jacobson, Dawn L Hershman.   

Abstract

PURPOSE: For some women, adjuvant chemotherapy for nonmetastatic breast cancer decreases recurrences and increases survival; however, patient-physician decisions regarding chemotherapy receipt can be influenced by medical and nonmedical factors. PATIENTS AND METHODS: We used a prospective cohort design and multivariate modeling to investigate factors related to noninitiation of chemotherapy among women with newly diagnosed breast cancer recruited from three US sites. We interviewed patients at baseline and during treatment on sociodemographic, tumor, and treatment decision-making factors. Patients were categorized according to National Comprehensive Cancer Network guidelines as those for whom chemotherapy was definitely indicated, clinically discretionary, or discretionary based on age greater than 70 years.
RESULTS: Of 1,145 patients recruited, chemotherapy was clinically indicated for 392 patients, clinically discretionary for 459 patients, discretionary because of age for 169 patients, and not indicated for 93 patients; data were insufficient for 32 patients. Chemotherapy rates were 90% for those in whom chemotherapy was clinically indicated, 36% for those in whom it was discretionary because of clinical factors, and 19% for those in whom it was discretionary based on age greater than 70 years. Nonreceipt of chemotherapy was associated with older age, more negative beliefs about treatment efficacy, less positive beliefs about chemotherapy, and more concern about adverse effects. In the two discretionary groups, clinical predictors of worse outcome (greater tumor size, positive nodes, worse grade, and estrogen receptor- and progesterone receptor-negative status) were associated with increased chemotherapy initiation.
CONCLUSION: Utilization of adjuvant chemotherapy was most common among patients who, based on clinical criteria, would most likely benefit from it, patients with more positive than negative beliefs regarding treatment efficacy, and patients with few concerns about adverse effects.

Entities:  

Mesh:

Year:  2012        PMID: 23008305      PMCID: PMC3478575          DOI: 10.1200/JCO.2012.43.8168

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  43 in total

Review 1.  Chemotherapy-induced nausea and vomiting.

Authors:  Paul J Hesketh
Journal:  N Engl J Med       Date:  2008-06-05       Impact factor: 91.245

2.  Use of adjuvant systemic therapy for early breast cancer among women 65 years of age and older.

Authors:  Bijal A Balasubramanian; Sampada K Gandhi; Kitaw Demissie; David A August; Betsy Kohler; Omowunmi Y Osinubi; George G Rhoads
Journal:  Cancer Control       Date:  2007-01       Impact factor: 3.302

3.  Psychosocial factors and patients' preferences for adjuvant chemotherapy in early breast cancer.

Authors:  Vlatka M Duric; Phyllis N Butow; Louise Sharpe; Frances Boyle; Jane Beith; Nicholas R C Wilcken; Stephane Heritier; Alan S Coates; R John Simes; Martin R Stockler
Journal:  Psychooncology       Date:  2007-01       Impact factor: 3.894

4.  Lost opportunities: physicians' reasons and disparities in breast cancer treatment.

Authors:  Nina A Bickell; Felice LePar; Jason J Wang; Howard Leventhal
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

5.  Underuse of breast cancer adjuvant treatment: patient knowledge, beliefs, and medical mistrust.

Authors:  Nina A Bickell; Jessica Weidmann; Kezhen Fei; Jenny J Lin; Howard Leventhal
Journal:  J Clin Oncol       Date:  2009-09-21       Impact factor: 44.544

6.  Influence of private practice setting and physician characteristics on the use of breast cancer adjuvant chemotherapy for elderly women.

Authors:  Dawn L Hershman; Donna Buono; Russell B McBride; Wei Yann Tsai; Alfred I Neugut
Journal:  Cancer       Date:  2009-09-01       Impact factor: 6.860

7.  Racial and socioeconomic disparities in adjuvant chemotherapy for older women with lymph node-positive, operable breast cancer.

Authors:  Alessia Bhargava; Xianglin L Du
Journal:  Cancer       Date:  2009-07-01       Impact factor: 6.860

8.  Adjuvant hormonal therapy use among insured, low-income women with breast cancer.

Authors:  Gretchen Kimmick; Roger Anderson; Fabian Camacho; Monali Bhosle; Wenke Hwang; Rajesh Balkrishnan
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

9.  Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.

Authors:  Hyman B Muss; Donald A Berry; Constance Cirrincione; Daniel R Budman; I Craig Henderson; Marc L Citron; Larry Norton; Eric P Winer; Clifford A Hudis
Journal:  J Clin Oncol       Date:  2007-08-20       Impact factor: 44.544

10.  Psychosocial influences on suboptimal adjuvant breast cancer treatment adherence among African American women: implications for education and intervention.

Authors:  Carol Magai; Nathan S Consedine; Brenda A Adjei; Dawn Hershman; Alfred Neugut
Journal:  Health Educ Behav       Date:  2007-10-01
View more
  12 in total

1.  Association Between Complementary and Alternative Medicine Use and Breast Cancer Chemotherapy Initiation: The Breast Cancer Quality of Care (BQUAL) Study.

Authors:  Heather Greenlee; Alfred I Neugut; Laura Falci; Grace Clarke Hillyer; Donna Buono; Jeanne S Mandelblatt; Janise M Roh; Isaac J Ergas; Marilyn L Kwan; Marion Lee; Wei Yann Tsai; Zaixing Shi; Lois Lamerato; Lawrence H Kushi; Dawn L Hershman
Journal:  JAMA Oncol       Date:  2016-09-01       Impact factor: 31.777

2.  Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer.

Authors:  Alfred I Neugut; Grace Clarke Hillyer; Lawrence H Kushi; Lois Lamerato; Nicole Leoce; Christine B Ambrosone; Dana H Bovbjerg; Jeanne S Mandelblatt; Dawn L Hershman
Journal:  Breast Cancer       Date:  2014-06-06       Impact factor: 4.239

3.  The diffusion of docetaxel in patients with metastatic prostate cancer.

Authors:  Joseph M Unger; Dawn L Hershman; Diane Martin; Ruth B Etzioni; William E Barlow; Michael LeBlanc; Scott R Ramsey
Journal:  J Natl Cancer Inst       Date:  2014-12-24       Impact factor: 13.506

4.  Impact of high-deductible insurance on adjuvant hormonal therapy use in breast cancer.

Authors:  Christine Y Lu; Fang Zhang; Anita K Wagner; Larissa Nekhlyudov; Craig C Earle; Matthew Callahan; Robert LeCates; Xin Xu; Dennis Ross-Degnan; J Frank Wharam
Journal:  Breast Cancer Res Treat       Date:  2018-05-12       Impact factor: 4.872

5.  Variations in Guideline-Concordant Breast Cancer Adjuvant Therapy in Rural Georgia.

Authors:  Gery P Guy; Joseph Lipscomb; Theresa W Gillespie; Michael Goodman; Lisa C Richardson; Kevin C Ward
Journal:  Health Serv Res       Date:  2014-12-10       Impact factor: 3.402

6.  Assessing racial/ethnic disparities in chemotherapy treatment among breast cancer patients in context of changing treatment guidelines.

Authors:  Abigail Silva; Garth H Rauscher; Kent Hoskins; Ruta Rao; Carol Estwing Ferrans
Journal:  Breast Cancer Res Treat       Date:  2013-11-22       Impact factor: 4.872

7.  Interpersonal influences and attitudes about adjuvant therapy treatment decisions among non-metastatic breast cancer patients: an examination of differences by age and race/ethnicity in the BQUAL study.

Authors:  Rachel C Shelton; Grace Clarke Hillyer; Dawn L Hershman; Nicole Leoce; Dana H Bovbjerg; Jeanne S Mandelblatt; Lawrence H Kushi; Lois Lamerato; S David Nathanson; Christine B Ambrosone; Alfred I Neugut
Journal:  Breast Cancer Res Treat       Date:  2012-12-22       Impact factor: 4.872

8.  A prospective cohort study of early discontinuation of adjuvant chemotherapy in women with breast cancer: the breast cancer quality of care study (BQUAL).

Authors:  Alfred I Neugut; Grace Clarke Hillyer; Lawrence H Kushi; Lois Lamerato; Donna L Buono; S David Nathanson; Dana H Bovbjerg; Jeanne S Mandelblatt; Wei-Yann Tsai; Judith S Jacobson; Dawn L Hershman
Journal:  Breast Cancer Res Treat       Date:  2016-06-10       Impact factor: 4.872

9.  Exploring patient- and physician-related factors preventing breast cancer patients from guideline-adherent adjuvant chemotherapy-results from the prospective multi-center study BRENDA II.

Authors:  Lukas Schwentner; Reyn Van Ewijk; Thorsten Kühn; Felix Flock; Riccardo Felberbaum; Maria Blettner; Rolf Kreienberg; Wolfgang Janni; Achim Wöckel; Susanne Singer
Journal:  Support Care Cancer       Date:  2016-01-27       Impact factor: 3.603

10.  Healthcare System Distrust, Physician Trust, and Patient Discordance with Adjuvant Breast Cancer Treatment Recommendations.

Authors:  Lorraine T Dean; Shadiya L Moss; Anne Marie McCarthy; Katrina Armstrong
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-09-29       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.